NasdaqGS - Delayed Quote USD
Arbutus Biopharma Corporation (ABUS)
3.5300
-0.0500
(-1.40%)
At close: June 13 at 4:00:02 PM EDT
3.6000
+0.07
+(1.98%)
After hours: June 13 at 5:54:46 PM EDT
Research Analysis
Earnings Estimate
| Currency in CAD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.09 | -0.08 | -0.43 | -0.38 |
| Low Estimate | -0.1 | -0.1 | -0.45 | -0.41 |
| High Estimate | -0.08 | -0.07 | -0.42 | -0.35 |
| Year Ago EPS | -0.15 | -0.14 | -0.54 | -0.43 |
Revenue Estimate
| Currency in CAD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | 2.22M | 2.19M | 7.85M | 6.18M |
| Low Estimate | 1.4M | 1.26M | 5.18M | 3.92M |
| High Estimate | 2.52M | 2.52M | 9.92M | 9.86M |
| Year Ago Sales | 2.39M | 1.86M | 8.8M | 7.85M |
| Sales Growth (year/est) | -6.92% | 18.02% | -10.84% | -21.28% |
Earnings History
| Currency in CAD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.13 | -0.13 | -0.12 | -0.15 |
| EPS Actual | -0.15 | -0.14 | -0.1 | -0.18 |
| Difference | -0.02 | -0.01 | 0.02 | -0.03 |
| Surprise % | -16.93% | -6.91% | 14.48% | -18.14% |
EPS Trend
| Currency in CAD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.09 | -0.08 | -0.43 | -0.38 |
| 7 Days Ago | -0.06 | -0.06 | -0.33 | -0.14 |
| 30 Days Ago | -0.06 | -0.06 | -0.33 | -0.14 |
| 60 Days Ago | -0.12 | -0.12 | -0.48 | -0.59 |
| 90 Days Ago | -0.12 | -0.12 | -0.47 | -0.57 |
EPS Revisions
| Currency in CAD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 3 | 1 |
| Up Last 30 Days | 2 | 2 | 3 | 1 |
| Down Last 7 Days | -- | -- | 1 | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ABUS | 40.25% | 39.37% | 20.02% | 12.92% |
| S&P 500 | 13.13% | 2.40% | 7.54% | 14.08% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 3/28/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/21/2025 |
| Maintains | Chardan Capital: Buy to Buy | 11/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/7/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/7/2024 |
Related Tickers
ROIV Roivant Sciences Ltd.
11.32
-1.31%
IMVT Immunovant, Inc.
15.66
-1.76%
ARWR Arrowhead Pharmaceuticals, Inc.
15.74
-2.96%
BRNS Barinthus Biotherapeutics plc
0.9033
-3.27%
ATHE Alterity Therapeutics Limited
4.4000
-4.14%
AUTL Autolus Therapeutics plc
2.1200
-1.40%
ALNY Alnylam Pharmaceuticals, Inc.
307.99
+1.09%
MREO Mereo BioPharma Group plc
2.7600
-0.72%
VNDA Vanda Pharmaceuticals Inc.
4.5100
-2.59%
AUPH Aurinia Pharmaceuticals Inc.
8.18
-0.61%